Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The Renin-Angiotensin Aldosterone System (RAAS) plays an important role not only in salt and water homeostasis but also in the cardiovascular system, the kidney, and the brain. While several volumes address different aspects of the RAAS function, this book provides cutting-edge information on the pathogenesis of various disorders related to RAAS overactivation. It also presents unique aspects of RAAS functioning that have not been sufficiently described in the literature. Topics covered include assessment of hypoaldosteronism in infancy, RASS and cognitive decline, and the role of RAAS in the pathogenesis of COVID-19. Written by experts in the field in an easy-to-follow and illustrated format, this volume will benefit students and practitioners, as well as clinical and basic science investigators alike.

Renin-angiotensin system. --- Angiotensins.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The Renin-Angiotensin Aldosterone System (RAAS) plays an important role not only in salt and water homeostasis but also in the cardiovascular system, the kidney, and the brain. While several volumes address different aspects of the RAAS function, this book provides cutting-edge information on the pathogenesis of various disorders related to RAAS overactivation. It also presents unique aspects of RAAS functioning that have not been sufficiently described in the literature. Topics covered include assessment of hypoaldosteronism in infancy, RASS and cognitive decline, and the role of RAAS in the pathogenesis of COVID-19. Written by experts in the field in an easy-to-follow and illustrated format, this volume will benefit students and practitioners, as well as clinical and basic science investigators alike.

Renin-angiotensin system. --- Angiotensins.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

A new antihypertensive drugs class has been newly developed: the renin inhibitors. Aliskiren, a new drug which act on the renin-angiotensin-aldosteron system by inhibiting the renin has recently been discovered. He was discovered by structure-based drug design when researchers were looking for a non-peptidic renin inhibitor thinking that it could have interesting antihypertensive properties. Once aliskiren discovered, lots of studies have been made to know its security and its efficacy. The first studies were made in animals (monkey, mice, rat and rabbit): they were mainly efficacy and toxicity studies. As the results of these studies were in favour of aliskiren, studies on men could be run. A lot of studies on men were or are being made. These studies were also about efficacy and security as compare the efficacy of aliskiren with placebo, ACE inhibitors and ARB (angiotensin receptor blockers), its long-term efficacy, its protective effects on cardiac an renal level, … These studies provided favourable results for aliskiren: significantly superior to placebo and similar or even superior to ACE inhibitors and ARB, beneficial effect on cardiac and renal level and placebo, ACE inhibitors and ARB-like security Une nouvelle classe de médicaments antihypertenseurs a récemment été développée : les inhibiteurs de la rénine. L’aliskirène est un nouveau médicament qui agit au niveau du système rénine-angiotensine-aldostérone en inhibant la rénine. La découverte de l’aliskirène s’est faite par structure-based drug design en recherchant des inhibiteurs non peptidiques de la rénine car ils ont un effet antihypertenseur prometteur. Une fois l’aliskirène découvert, de nombreuses études ont été réalisées afin de connaître sa sécurité et son efficacité. Les premières études ont consisté en des études réalisées chez l’animal (rat, souris, lapin, singe) : ces études sont principalement des études d’efficacité et de toxicité de l’aliskirène. Les résultats de ces études chez l’homme concernent aussi sa sécurité et son efficacité. De nombreuses études ont été réalisées ou sont en cours telle que : comparer les effets de l’aliskirène au placebo, aux IECA, au Sartans, étudier son efficacité à long terme, étudier son effet protecteur au niveau cardiaque et au niveau rénal, … Ces études ont fourni des résultats favorables pour l’aliskirène : une efficacité significativement supérieure au placebo et similaire voire supérieure aux IECA et aux Sartans, un effet favorable au niveau cardiaque et rénal mais aussi une sécurité semblable au placebo et aux IECA et Sartans

Hypertension --- Antihypertensive Agents --- Renin-Angiotensin System --- Aliskiren

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Renal hypertension --- Kidneys --- Renin-angiotensin system --- Blood pressure

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Renal hypertension --- Renin-angiotensin system --- Renin --- Saralasin --- Diagnosis